EcoDrugPlus

Ribosomal Protein L38

Ensembl ID : ENSXETG00000025319
Gene Symbol: RPL38
5 View Cross-references
198 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L4

Ensembl ID : ENSXETG00000015898
Gene Symbol: RPL4
10 Enzyme and pathways 5 View Cross-references
342 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L5

Ensembl ID : ENSXETG00000023004
Gene Symbol: RPL5
10 Enzyme and pathways 5 View Cross-references
534 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L6

Ensembl ID : ENSXETG00000004304
Gene Symbol: RPL6
5 View Cross-references
483 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L7

Ensembl ID : ENSXETG00000025457
Gene Symbol: RPL7
10 Enzyme and pathways 5 View Cross-references
492 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L7a

Ensembl ID : ENSXETG00000042208
Gene Symbol: RPL7A
5 View Cross-references
372 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L8

Ensembl ID : ENSXETG00000015483
Gene Symbol: RPL8
10 Enzyme and pathways 5 View Cross-references
265 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein L9

Ensembl ID : ENSXETG00000012856
Gene Symbol: RPL9
10 Enzyme and pathways 5 View Cross-references
502 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein S10

Ensembl ID : ENSXETG00000015129
Gene Symbol: RPS10
14 Enzyme and pathways 5 View Cross-references
382 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein S11

Ensembl ID : ENSXETG00000043869
Gene Symbol: RPS11
14 Enzyme and pathways 5 View Cross-references
279 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein S12

Ensembl ID : ENSXETG00000000109
Gene Symbol: RPS12
14 Enzyme and pathways 5 View Cross-references
289 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Ribosomal Protein S13

Ensembl ID : ENSXETG00000026454
Gene Symbol: RPS13
14 Enzyme and pathways 5 View Cross-references
172 Possible Orthologues:


Display Options: Drug type Mechanism of Action Route of Adminstration Status Therapeutic Area Therapeutic Indication

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).